Chronic myeloid leukaemia: Biology and therapy

Blood Rev. 2024 May:65:101196. doi: 10.1016/j.blre.2024.101196. Epub 2024 Mar 27.

Abstract

Chronic myeloid leukaemia (CML) is caused by BCR::ABL1. Tyrosine kinase-inhibitors (TKIs) are the initial therapy. Several organizations have reported milestones to evaluate response to initial TKI-therapy and suggest when a change of TKI should be considered. Achieving treatment-free remission (TFR) is increasingly recognized as the optimal therapy goal. Which TKI is the best initial therapy for which persons and what depth and duration of molecular remission is needed to achieve TFR are controversial. In this review we discuss these issues and suggest future research directions.

Keywords: BCR::ABL1; Chronic myeloid leukaemia; Quality-of-life; Treatment-free remission; Tyrosine kinase inhibitor.

Publication types

  • Review

MeSH terms

  • Biology
  • Fusion Proteins, bcr-abl / genetics
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / diagnosis
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / etiology
  • Protein Kinase Inhibitors* / therapeutic use
  • Remission Induction

Substances

  • Protein Kinase Inhibitors
  • Fusion Proteins, bcr-abl